EFFECTS OF INTERFERON-ALPHA MONOTHERAPY ON HEPATIC DRUG-METABOLISM INCANCER-PATIENTS

1 The influence of interferon-alpha (IFNalpha) on the clearances of th eophylline (TH), antipyrine (AP) and hexobarbitone (HB) was studied in seven cancer patients given IFNalpha as their only treatment. In addi tion, IFNalpha effects on drug clearance were correlated with changes in serum inflammatory cytokines and acute phase proteins. 2 A 'baselin e' study was performed by administering an oral drug 'cocktail' of TH (150 mg), AP (250 mg) and HB (250 mg) with saline injected simultaneou sly and again 24 h later. One week later, an 'acute' study was perform ed at the initiation of IFNalpha therapy, 3 X 10(6) units injected wit h the drug cocktail and again 24 h later. After 2 weeks of IFNalpha tr eatment three times per week, a 'chronic' study was performed with IFN alpha injected the day prior to, simultaneously with, as well as 24 h after the drug cocktail. 3 Plasma samples were collected over 48 h and the clearances of TH, AP and HB were estimated. Serum samples were co llected at various times for the measurement of tumor necrosis factor (TNF), interleukin-I (IL-1), interleukin-6 (IL-6), C-reactive protein (C-RP) and alpha1-acid glycoprotein (AGP). 4 IFNalpha caused a 33% dec rease in the oral clearance of TH during the chronic study compared wi th baseline (P less-than-or-equal-to 0.05). Although IFNalpha inhibite d TH clearance by 16% during the acute study and AP clearance by 20-21 % during both acute and chronic studies, these changes did not reach s tatistical significance. IFNalpha caused minimal changes in HB clearan ce. There were no chronic effects of IFNalpha on serum cytokines or ac ute phase proteins. 5 The findings confirm that the most commonly used dose of IFNalpha inhibits the hepatic clearance in humans of some but not all drugs and that this inhibition persists during IFNalpha thera py. Because inhibition was not associated with increases in serum cyto kines or acute phase proteins, the mechanism by which IFNalpha inhibit s cytochrome P450 activities in vivo does not appear to involve inflam matory mediators such as TNF, IL-1 or IL-6.